Trials / Completed
CompletedNCT01837420
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 80mg | |
| DRUG | VB-201 160mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2013-04-23
- Last updated
- 2015-03-27
Locations
4 sites across 4 countries: Germany, Israel, Poland, Spain
Source: ClinicalTrials.gov record NCT01837420. Inclusion in this directory is not an endorsement.